These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
398 related items for PubMed ID: 3799612
1. Food and Drug Administration monitoring of adverse drug reactions. Sills JM, Tanner LA, Milstien JB. Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612 [Abstract] [Full Text] [Related]
2. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, Evens A, Trifilio SM, Courtney DM, Raisch DW. Arch Intern Med; 2007 May 28; 167(10):1041-9. PubMed ID: 17533207 [Abstract] [Full Text] [Related]
4. Improved reporting of adverse drug reactions. Kimelblatt BJ, Young SH, Heywood PM, Mandala AR, Gendelman S, Mehl B. Am J Hosp Pharm; 1988 May 28; 45(5):1086-9. PubMed ID: 3400650 [Abstract] [Full Text] [Related]
5. Use of a database computer program to identify trends in reporting of adverse drug reactions. Johnston PE, Morrow JD, Branch RA. Am J Hosp Pharm; 1990 Jun 28; 47(6):1321-7. PubMed ID: 2368725 [Abstract] [Full Text] [Related]
6. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. Ladewski LA, Belknap SM, Nebeker JR, Sartor O, Lyons EA, Kuzel TC, Tallman MS, Raisch DW, Auerbach AR, Schumock GT, Kwaan HC, Bennett CL. J Clin Oncol; 2003 Oct 15; 21(20):3859-66. PubMed ID: 14551305 [Abstract] [Full Text] [Related]
9. National adverse drug reaction reporting. 1984-1989. Faich GA. Arch Intern Med; 1991 Aug 15; 151(8):1645-7. PubMed ID: 1872669 [Abstract] [Full Text] [Related]
10. Use and reported adverse effects of new chemical entities. Kennedy DL, Goetsch RA, Dreis MW. Am J Hosp Pharm; 1989 Mar 15; 46(3):558-65. PubMed ID: 2719041 [Abstract] [Full Text] [Related]
12. A pharmaceutical manufacturer's perspective on reporting adverse drug experiences. Sullivan JW. Am J Hosp Pharm; 1990 Jun 15; 47(6):1342-5. PubMed ID: 2368728 [Abstract] [Full Text] [Related]
13. Improving adverse drug reaction reporting in the community setting. McCloskey BA. Med Interface; 1996 May 15; 9(5):85-7. PubMed ID: 10157690 [Abstract] [Full Text] [Related]
15. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway. Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM. Pharmacoepidemiol Drug Saf; 2007 Sep 15; 16(9):999-1005. PubMed ID: 17457794 [Abstract] [Full Text] [Related]
16. National adverse drug reaction surveillance. 1986. Faich GA, Dreis M, Tomita D. Arch Intern Med; 1988 Apr 15; 148(4):785-7. PubMed ID: 3355297 [Abstract] [Full Text] [Related]
19. Evaluation of efficacy of heartworm preventive products at the FDA. Hampshire VA. Vet Parasitol; 2005 Oct 24; 133(2-3):191-5. PubMed ID: 16099105 [Abstract] [Full Text] [Related]
20. Program coordinated by a drug information service to improve adverse drug reaction reporting in a hospital. Michel DJ, Knodel LC. Am J Hosp Pharm; 1986 Sep 24; 43(9):2202-5. PubMed ID: 3766573 [Abstract] [Full Text] [Related] Page: [Next] [New Search]